Again, combined with the previous literature, we speculated that small doses of aromatase inhibitor therapy, along with TRT, to adjust the balance of T/E ratios may have preventive and therapeutic effects on BPH and MetS in clinical procedures [11–16, 28, 29]. Here, CYP19A1 is linked to metabolic syndrome.